Ixiaro Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Ixiaro market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to heightened awareness of Japanese encephalitis, government-led initiatives, increased travel to endemic regions, improvements in healthcare infrastructure, and the growing demand for effective vaccination.

Growth during the market's forecast period can be attributed to the rising incidence of Japanese encephalitis, increasing public awareness and health campaigns, the expansion of vaccine distribution networks, government funding and policies, and the growth in medical tourism. Key trends for the forecast period include market expansion into new regions, regulatory approvals fostering growth, increased awareness of mosquito-borne diseases, advancements in technology, and a rising demand for ixiaro.

The increasing incidence of Japanese encephalitis is expected to drive the growth of the ixiaro market in the future. Japanese encephalitis (JE) is a viral infection transmitted by mosquitoes that can cause severe neurological disease in some cases. The rise in JE cases is linked to factors such as intensified rice irrigation, population growth, and expanded pig farming, which create favorable conditions for mosquito breeding and virus transmission in endemic areas. Ixiaro, a vaccine developed to protect against Japanese encephalitis, plays a crucial role in preventing the viral infection by stimulating the immune system to produce antibodies that offer long-term protection. Without treatment, the disease can lead to severe neurological damage and death. For example, in August 2024, the World Health Organization (WHO) reported an estimated 100,000 clinical cases of Japanese encephalitis globally each year, with approximately 25,000 deaths. Therefore, the rising incidence of Japanese encephalitis is driving the ixiaro market.

The increasing number of clinical trials is also expected to contribute to the growth of the ixiaro market. Clinical trials are research studies designed to assess the safety, efficacy, and potential side effects of medical treatments, drugs, or devices in humans. The growing number of clinical trials reflects advances in science, the expanding scope of medical research, and the increasing complexity of healthcare needs. Ixiaro, as a Japanese encephalitis vaccine, supports these trials by allowing researchers to evaluate its efficacy, safety, and immune responses across different populations, which enhances the development of effective treatments and improves trial outcomes in regions affected by the disease. For instance, in November 2023, the Association of the British Pharmaceutical Industry reported a 4.3% increase in the number of industry-sponsored clinical trials initiated in the UK, rising from 394 trials in 2021 to 411 in 2022. Thus, the rising number of clinical trials is fueling the growth of the ixiaro market.

The increasing trend of personalized medicine is expected to further propel the growth of the ixiaro market. Personalized medicine involves tailoring treatments and healthcare strategies to the specific characteristics of individual patients, including their genetic makeup, lifestyle, and environment, to achieve optimal outcomes. This rise is driven by advancements in genomic technologies, a better understanding of molecular biology, the growing availability of precision diagnostic tools, and the increasing demand for targeted therapies that enhance patient outcomes while reducing side effects. Ixiaro supports personalized medicine by offering tailored protection based on individual risk factors, such as geographical exposure and health conditions, enhancing immunization strategies for travelers and those in endemic regions. For instance, in 2023, the Personalized Medicine Coalition reported that 34% of new drugs approved by the FDA in 2022 were personalized medicines, with at least 25% of new drugs in the previous eight years also falling under this category. As a result, the rise in personalized medicine is driving the ixiaro market.

The key company operating in the ixiaro market is Valneva Austria GmbH.

North America was the largest region in the ixiaro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ixiaro report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ixiaro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ixiaro is a vaccine designed to protect against Japanese encephalitis (JE), a viral infection transmitted by mosquitoes that can lead to severe brain inflammation. It is made from an inactivated form of the Japanese encephalitis virus and is mainly recommended for travelers visiting regions where JE is common. The vaccine is given in two doses, typically 28 days apart, providing effective protection against the disease.

The primary types of ixiaro vaccines are cell culture-derived inactivated vaccines and others. The cell culture-derived inactivated vaccine is produced by cultivating the virus in a laboratory environment, specifically in cell cultures. The virus is then inactivated, meaning it can no longer cause disease, but still prompts the immune system to generate a defense against the actual virus. The vaccine is indicated for Japanese encephalitis and other conditions, and it is suitable for pediatric patients, adults, and high-risk groups. Distribution occurs through hospitals, private clinics, public health clinics, pharmacies, and mobile vaccination units, and it is used for routine immunization, travel vaccination, and post-exposure prophylaxis.

The ixiaro market research report is one of a series of new reports that provides ixiaro market statistics, including ixiaro industry global market size, regional shares, competitors with a ixiaro market share, detailed ixiaro market segments, market trends and opportunities, and any further data you may need to thrive in the ixiaro industry. This ixiaro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Ixiaro market consists of sales of the Japanese encephalitis vaccine, dukoral for cholera, and enterotoxigenic escherichia coli (ETEC) diarrhea. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.